Procalcitonin as a biomarker to guide treatments for patients with lower respiratory tract infections

References

• Prestinaci F, Pezzotti P, Pantosti A. Antimicrobial resistance: a global multifaceted phenomenon. Pathog Glob Health. 2015;109:309–318. doi: 10.1179/2047773215Y.0000000030
   PubMed Web of Science ®Google Scholar
• Póvoa P, Coelho L, Dal-Pizzol F, et al. How to use biomarkers of infection or sepsis at the bedside: guide to clinicians. Intensive care Med. 2023;49(2):142–153. doi: 10.1007/s00134-022-06956-y
   PubMed Web of Science ®Google Scholar
• Pierrakos C, Velissaris D, Bisdorff M, et al. Biomarkers of sepsis: time for a reappraisal. Crit Care. 2020;24:287. doi: 10.1186/s13054-020-02993-5
   PubMed Web of Science ®Google Scholar
• Vijayan AL, Vanimaya RS, Saikant R, et al. Procalcitonin: a promising diagnostic marker for sepsis and antibiotic therapy. J Intensive Care. 2017;5:51. doi: 10.1186/s40560-017-0246-8
   PubMed Web of Science ®Google Scholar
• Albrich WC, Harbarth S. Pros and cons of using biomarkers versus clinical decisions in start and stop decisions for antibiotics in the critical care setting. Intensive care Med. 2015;41:1739–1751. doi: 10.1007/s00134-015-3978-8
   PubMed Web of Science ®Google Scholar
• Becker K. Procalcitonin: How a hormone became a marker and mediator of sepsis. Swiss Med Wkly. 2001. doi: 10.4414/smw.2001.09751
   PubMed Web of Science ®Google Scholar
• Hamade B, Huang DT. Procalcitonin. Crit Care Clin. 2020;36:23–40. doi: 10.1016/j.ccc.2019.08.003
   PubMed Web of Science ®Google Scholar
• Bréchot N, Hékimian G, Chastre J, et al. Procalcitonin to guide antibiotic therapy in the ICU. Int J Antimicrob Agents. 2015:46;S19–24. doi: 10.1016/j.ijantimicag.2015.10.012
   PubMed Web of Science ®Google Scholar
• Müller B, White JC, Nylén ES, et al. Ubiquitous expression of the calcitonin-I gene in multiple tissues in response to sepsis 1. J Clin Endocrinol Metab. 2001;86(1):396–404. doi: 10.1210/jcem.86.1.7089
   PubMed Web of Science ®Google Scholar
• Russwurm S, Wiederhold M, Oberhoffer M, et al. Molecular aspects and natural source of procalcitonin. Cclm. 1999;37:789–797. doi: 10.1515/CCLM.1999.119
   Google Scholar
• Linscheid P, Seboek D, Schaer DJ, et al. Expression and secretion of procalcitonin and calcitonin gene-related peptide by adherent monocytes and by macrophage-activated adipocytes*. Crit Care Med. 2004;32:1715–1721. doi: 10.1097/01.CCM.0000134404.63292.71
   PubMed Web of Science ®Google Scholar
• Production of procalcitonin (PCT) in non-thyroidal tissue after LPS injection. Horm Metab Res. 2003;35:290–295. doi: 10.1055/s-2003-41304
   PubMed Web of Science ®Google Scholar
• Meisner M, Schmidt J, Htittner H, et al. The natural elimination rate of procalcitonin in patients with normal and impaired renal function. n.d.
   Google Scholar
• Mimoz O, Edouard AR, Samii K, et al. Procalcitonin and C-reactive protein during the early posttraumatic systemic inflammatory response syndrome. Intensive care Med. 1998;24:185–188. doi: 10.1007/s001340050543
   PubMed Web of Science ®Google Scholar
• Mofidi R, Suttie SA, Patil PV, et al. The value of procalcitonin at predicting the severity of acute pancreatitis and development of infected pancreatic necrosis: systematic review. Surgery. 2009;146:72–81. doi: 10.1016/j.surg.2009.02.013
   PubMed Web of Science ®Google Scholar
• Aouifi A, Piriou V, Bastien O, et al. Usefulness of procalcitonin for diagnosis of infection in cardiac surgical patients. Crit Care Med. 2000;28(9):3171–3176. doi: 10.1097/00003246-200009000-00008
   PubMed Web of Science ®Google Scholar
• Bro-Jeppesen J, Kjaergaard J, Wanscher M, et al. Systemic inflammatory response and potential prognostic implications after out-of-hospital cardiac arrest: a substudy of the target temperature management trial*. Crit Care Med. 2015;43(6):1223–1232. doi: 10.1097/CCM.0000000000000937
   PubMed Web of Science ®Google Scholar
• Li X, Wang X, Li S, et al. Diagnostic value of procalcitonin on early Postoperative infection after Pediatric cardiac surgery. Pediatr Crit Care Med. 2017;18(5):420–428. doi: 10.1097/PCC.0000000000001118
   PubMed Web of Science ®Google Scholar
• Chastre J, Fagon JY, Bornet-Lecso M, et al. Evaluation of bronchoscopic techniques for the diagnosis of nosocomial pneumonia. Am J Respir Crit Care Med. 1995:152;231–240. doi: 10.1164/ajrccm.152.1.7599829
   PubMed Web of Science ®Google Scholar
• Chastre J, Fagon J-Y. Ventilator-associated pneumonia. Am J Respir Crit Care Med. 2002;165:867–903.
   PubMed Web of Science ®Google Scholar
• Branche A, Neeser O, Mueller B, et al. Procalcitonin to guide antibiotic decision making. Curr Opin Infect Dis. 2019;32:130–135. doi: 10.1097/QCO.0000000000000522
   PubMed Web of Science ®Google Scholar
• Müller B, Harbarth S, Stolz D, et al. Diagnostic and prognostic accuracy of clinical and laboratory parameters in community-acquired pneumonia. BMC Infect Dis. 2007;7:10. doi: 10.1186/1471-2334-7-10
   PubMed Web of Science ®Google Scholar
• Kamat IS, Ramachandran V, Eswaran H, et al. Procalcitonin to Distinguish viral from bacterial pneumonia: a systematic review and meta-analysis. Clin Infect Dis. 2020;70(3):538–542. doi: 10.1093/cid/ciz545
   PubMed Web of Science ®Google Scholar
• Self WH, Balk RA, Grijalva CG, et al. Procalcitonin as a marker of Etiology in adults hospitalized with community-acquired pneumonia. Clin Infect Dis. 2017;65:183–190. doi: 10.1093/cid/cix317
   PubMed Web of Science ®Google Scholar
• Boussekey N, Leroy O, Alfandari S, et al. Procalcitonin kinetics in the prognosis of severe community-acquired pneumonia. Intensive care Med. 2006;32:469–472. doi: 10.1007/s00134-005-0047-8
   PubMed Web of Science ®Google Scholar
• Rodríguez AH, Avilés-Jurado FX, Díaz E, et al. Procalcitonin (PCT) levels for ruling-out bacterial coinfection in ICU patients with influenza: A CHAID decision-tree analysis. J Infect. 2016;72:143–151. doi: 10.1016/j.jinf.2015.11.007
   PubMed Web of Science ®Google Scholar
• Musher DM, Roig IL, Cazares G, et al. Can an etiologic agent be identified in adults who are hospitalized for community-acquired pneumonia: Results of a one-year study. J Infect. 2013;67:11–18. doi: 10.1016/j.jinf.2013.03.003
   PubMed Web of Science ®Google Scholar
• Daubin C, Parienti J-J, Fradin S, et al. Procalcitonin levels and bacterial aetiology among COPD patients admitted to the ICU with severe pneumonia: a prospective cohort study. BMC Infect Dis. 2009;9:157. doi: 10.1186/1471-2334-9-157
   PubMed Web of Science ®Google Scholar
• Hirakata Y, Yanagihara K, Kurihara S, et al. Comparison of usefulness of plasma procalcitonin and C-reactive protein measurements for estimation of severity in adults with community-acquired pneumonia. Diagn Microbiol Infect Dis. 2008;61:170–174. doi: 10.1016/j.diagmicrobio.2008.01.014
   PubMed Web of Science ®Google Scholar
• Schuetz P, Suter-Widmer I, Chaudri A, et al. Prognostic value of procalcitonin in community-acquired pneumonia. Eur Respir J. 2011;37:384–392. doi: 10.1183/09031936.00035610
   PubMed Web of Science ®Google Scholar
• Nseir S, Martin-Loeches I, Povoa P, et al. Relationship between ventilator-associated pneumonia and mortality in COVID-19 patients: a planned ancillary analysis of the coVapid cohort. Crit Care. 2021;25:177. doi: 10.1186/s13054-021-03588-4
   PubMed Web of Science ®Google Scholar
• Rouzé A, Martin-Loeches I, Povoa P, et al. Early bacterial Identification among Intubated patients with COVID-19 or influenza pneumonia: A European multicenter Comparative clinical trial. Am J Respir Crit Care Med. 2021;204:546–556. doi: 10.1164/rccm.202101-0030OC
   PubMed Web of Science ®Google Scholar
• Saura O, Rouzé A, Martin-Loeches I, et al. Relationship between corticosteroid use and incidence of ventilator-associated pneumonia in COVID-19 patients: a retrospective multicenter study. Crit Care. 2022;26:292. doi: 10.1186/s13054-022-04170-2
   PubMed Web of Science ®Google Scholar
• Rozencwajg S, Pilcher D, Combes A, et al. Outcomes and survival prediction models for severe adult acute respiratory distress syndrome treated with extracorporeal membrane oxygenation. Crit Care. 2016;20:392. doi: 10.1186/s13054-016-1568-y
   PubMed Web of Science ®Google Scholar
• Martin-Loeches I, Povoa P, Rodríguez A, et al. Incidence and prognosis of ventilator-associated tracheobronchitis (TAVeM): a multicentre, prospective, observational study. Lancet Respir Med. 2015;3:859–868. doi: 10.1016/S2213-2600(15)00326-4
   PubMed Web of Science ®Google Scholar
• Klein EY, Monteforte B, Gupta A, et al. The frequency of influenza and bacterial coinfection: a systematic review and meta‐analysis. Influenza Other Respir Viruses. 2016;10:394–403. doi: 10.1111/irv.12398
   PubMed Web of Science ®Google Scholar
• Chertow DS, Memoli MJ. Bacterial coinfection in influenza: A Grand Rounds review. JAMA. 2013;309:275. doi: 10.1001/jama.2012.194139
   PubMed Web of Science ®Google Scholar
• Saura O, Chommeloux J, Levy D, et al. Updates in the management of respiratory virus infections in ICU patients: revisiting the non-SARS-CoV-2 pathogens. Expert Rev Anti Infect Ther. 2022;20(12):1537–1550. doi: 10.1080/14787210.2022.2134116
   PubMed Web of Science ®Google Scholar
• Cuquemelle E, Soulis F, Villers D, et al.; A/H1N1 REVA-SRLF Study Group. Can procalcitonin help identify associated bacterial infection in patients with severe influenza pneumonia? A multicentre study. Intensive care Med. 2011;37:796–800. doi: 10.1007/s00134-011-2189-1
   PubMed Web of Science ®Google Scholar
• Pfister R, Kochanek M, Leygeber T, et al. Procalcitonin for diagnosis of bacterial pneumonia in critically ill patients during 2009 H1N1 influenza pandemic: a prospective cohort study, systematic review and individual patient data meta-analysis. Crit Care. 2014;18(2):R44. doi: 10.1186/cc13760
   PubMed Web of Science ®Google Scholar
• Stolz D, Stulz A, Müller B, et al. BAL neutrophils, serum procalcitonin, and C-Reactive protein to predict bacterial infection in the immunocompromised Host. Chest. 2007;132:504–514. doi: 10.1378/chest.07-0175
   PubMed Web of Science ®Google Scholar
• Bele N, Darmon M, Coquet I, et al. Diagnostic accuracy of procalcitonin in critically ill immunocompromised patients. BMC Infect Dis. 2011;11:224. doi: 10.1186/1471-2334-11-224
   PubMed Web of Science ®Google Scholar
• Gautam S, Cohen AJ, Stahl Y, et al. Severe respiratory viral infection induces procalcitonin in the absence of bacterial pneumonia. Thorax. 2020;75(11):974–981. doi: 10.1136/thoraxjnl-2020-214896
   PubMed Web of Science ®Google Scholar
• Patel S, Wang S, Pauliks L, et al. Evaluation of a novel pulsatile extracorporeal life support system synchronized to the cardiac cycle: effect of rhythm changes on hemodynamic performance: pulsatile ECLS system during various cardiac rhythm. Artif Organs. 2015;39:67–76. doi: 10.1111/aor.12454
   PubMed Web of Science ®Google Scholar
• Malinverni S, Nuñez M, Cotton F, et al. Is procalcitonin a reliable marker of bacterial community-acquired pneumonia in adults admitted to the emergency department during SARS-CoV-2 pandemic? Eur J Emerg Med. 2021;28:312–314. doi: 10.1097/MEJ.0000000000000796
   PubMed Web of Science ®Google Scholar
• Heer RS, Mandal AK, Kho J, et al. Elevated procalcitonin concentrations in severe Covid-19 may not reflect bacterial co-infection. Ann Clin Biochem Int J Lab Med. 2021;58:520–527. doi: 10.1177/00045632211022380
   PubMed Web of Science ®Google Scholar
• Carbonell R, Moreno G, Martín-Loeches I, et al. Prognostic value of procalcitonin and C-Reactive protein in 1608 critically ill patients with severe influenza pneumonia 2021. Antibiotics. 2021;10(4):11. doi: 10.3390/antibiotics10040350
   Google Scholar
• Garrido P, Cueto P, Rovira C, et al. Clinical value of procalcitonin in critically ill patients infected by SARS-CoV-2. Am J Emerg Med. 2021;46:525–531. doi: 10.1016/j.ajem.2020.11.011
   PubMed Web of Science ®Google Scholar
• Liu Z-M, Li J-P, Wang S-P, et al. Association of procalcitonin levels with the progression and prognosis of hospitalized patients with COVID-19. Int J Med Sci. 2020;17:2468–2476. doi: 10.7150/ijms.48396
   PubMed Web of Science ®Google Scholar
• Kooistra EJ, van Berkel M, van Kempen NF, et al. Dexamethasone and tocilizumab treatment considerably reduces the value of C-reactive protein and procalcitonin to detect secondary bacterial infections in COVID-19 patients. Crit Care. 2021;25(1):281. doi: 10.1186/s13054-021-03717-z
   PubMed Web of Science ®Google Scholar
• van Berkel M, Kox M, Frenzel T, et al.; on behalf of the RCI-COVID-19 study group. Biomarkers for antimicrobial stewardship: a reappraisal in COVID-19 times? Crit Care. 2020;24:600. doi: 10.1186/s13054-020-03291-w
   PubMed Web of Science ®Google Scholar
• Tong-Minh K, van der Does Y, Engelen S, et al. High procalcitonin levels associated with increased intensive care unit admission and mortality in patients with a COVID-19 infection in the emergency department. BMC Infect Dis. 2022;22(1):165. doi: 10.1186/s12879-022-07144-5
   PubMed Web of Science ®Google Scholar
• Moreno-García E, Puerta-Alcalde P, Letona L, et al. Bacterial co-infection at hospital admission in patients with COVID-19. Int J Infect Dis. 2022;118:197–202.
   PubMed Web of Science ®Google Scholar
• Schuetz P, Christ-Crain M, Thomann R, et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: The ProHOSP randomized controlled trial. JAMA. 2009;302:1059. doi: 10.1001/jama.2009.1297
   PubMed Web of Science ®Google Scholar
• Christ-Crain M, Jaccard-Stolz D, Bingisser R, et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet. 2004;363:600–607. doi: 10.1016/S0140-6736(04)15591-8
   PubMed Web of Science ®Google Scholar
• Christ-Crain M, Stolz D, Bingisser R, et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med. 2006;174:84–93. doi: 10.1164/rccm.200512-1922OC
   PubMed Web of Science ®Google Scholar
• Huang DT, Yealy DM, Filbin MR, et al. Procalcitonin-guided use of antibiotics for lower respiratory tract infection. N Engl J Med. 2018;379:236–249. doi: 10.1056/NEJMoa1802670
   PubMed Web of Science ®Google Scholar
• Schuetz P, Briel M, Christ-Crain M, et al. Procalcitonin to guide initiation and duration of antibiotic treatment in acute respiratory infections: an individual patient data meta-analysis. Clin Infect Dis. 2012;55:651–662. doi: 10.1093/cid/cis464
   PubMed Web of Science ®Google Scholar
• Papazian L, Klompas M, Luyt C-E. Ventilator-associated pneumonia in adults: a narrative review. Intensive care Med. 2020;46:888–906. doi: 10.1007/s00134-020-05980-0
   PubMed Web of Science ®Google Scholar
• Reignier J, Mercier E, Boulain T, et al. Effect of not Monitoring Residual Gastric volume on risk of ventilator-associated pneumonia in adults Receiving mechanical ventilation and early Enteral Feeding. n.d.
   Google Scholar
• Fagon J-Y, Chastre J, Wolff M, et al. Invasive and noninvasive strategies for management of suspected ventilator-associated pneumonia: a randomized trial. Ann Intern Med. 2000;132:621. doi: 10.7326/0003-4819-132-8-200004180-00004
   PubMed Web of Science ®Google Scholar
• Forel J-M, Voillet F, Pulina D, et al. Ventilator-associated pneumonia and ICU mortality in severe ARDS patients ventilated according to a lung-protective strategy. Crit Care. 2012;16:R65. doi: 10.1186/cc11312
   PubMed Web of Science ®Google Scholar
• Bekaert M, Timsit J-F, Vansteelandt S, et al. Attributable mortality of ventilator-associated pneumonia: a reappraisal using causal analysis. Am J Respir Crit Care Med. 2011;184:1133–1139. doi: 10.1164/rccm.201105-0867OC
   PubMed Web of Science ®Google Scholar
• Rea-Neto A, Youssef N, Tuche F, et al. Diagnosis of ventilator-associated pneumonia: a systematic review of the literature. Crit Care. 2008;12:R56. doi: 10.1186/cc6877
   PubMed Web of Science ®Google Scholar
• Palazzo SJ, Simpson T, Schnapp L. Biomarkers for ventilator-associated pneumonia: Review of the literature. Heart Lung. 2011;40:293–298. doi: 10.1016/j.hrtlng.2010.11.003
   PubMed Web of Science ®Google Scholar
• Luyt C-E, Combes A, Reynaud C, et al. Usefulness of procalcitonin for the diagnosis of ventilator-associated pneumonia. Intensive care Med. 2008;34:1434–1440. doi: 10.1007/s00134-008-1112-x
   PubMed Web of Science ®Google Scholar
• Luyt C-E, Guérin V, Combes A, et al. Procalcitonin kinetics as a Prognostic marker of ventilator-associated pneumonia. Am J Respir Crit Care Med. 2005;171:48–53. doi: 10.1164/rccm.200406-746OC
   PubMed Web of Science ®Google Scholar
• Luyt C-E, Combes A, Trouillet J-L, et al. Biomarkers to optimize antibiotic therapy for pneumonia Due to multidrug-resistant pathogens. Clin Chest Med. 2011;32:431–438. doi: 10.1016/j.ccm.2011.05.004
   PubMed Web of Science ®Google Scholar
• Salluh JIF, Souza-Dantas VC, Póvoa P. The current status of biomarkers for the diagnosis of nosocomial pneumonias. Curr Opin Crit Care. 2017;23:391–397. doi: 10.1097/MCC.0000000000000442
   PubMed Web of Science ®Google Scholar
• Charles PE, Kus E, Aho S, et al. Serum procalcitonin for the early recognition of nosocomial infection in the critically ill patients: a preliminary reportVol. 9. BMC Infect Dis; 2009. p. 49. 10.1186/1471-2334-9-49
   Google Scholar
• Jung B, Embriaco N, Roux F, et al. Microbiogical data, but not procalcitonin improve the accuracy of the clinical pulmonary infection score. Intensive care Med. 2010;36:790–798. doi: 10.1007/s00134-010-1833-5
   PubMed Web of Science ®Google Scholar
• Jiao J, Wang M, Zhang J, et al. Procalcitonin as a diagnostic marker of ventilator-associated pneumonia in cardiac surgery patients. Exp Ther Med. 2015;9:1051–1057. doi: 10.3892/etm.2015.2175
   PubMed Web of Science ®Google Scholar
• Coelho L, Rabello L, Salluh J, et al. C-reactive protein and procalcitonin profile in ventilator-associated lower respiratory infections. J Crit Care. 2018;48:385–389. doi: 10.1016/j.jcrc.2018.09.036
   PubMed Web of Science ®Google Scholar
• Póvoa P, Martin-Loeches I, Ramirez P, et al. Biomarker kinetics in the prediction of VAP diagnosis: results from the BioVAP study. Ann Intensive Care. 2016;6:32. doi: 10.1186/s13613-016-0134-8
   PubMed Web of Science ®Google Scholar
• Linssen CFM, Bekers O, Drent M, et al. C-reactive protein and procalcitonin concentrations in bronchoalveolar lavage fluid as a predictor of ventilator-associated pneumonia. Ann Clin Biochem Int J Lab Med. 2008;45:293–298. doi: 10.1258/acb.2007.007133
   PubMed Web of Science ®Google Scholar
• Duflo F, Chassard DA, Procalcitonin S. Anesthesiology. 2002;96:74–79. doi: 10.1097/00000542-200201000-00018
   PubMed Web of Science ®Google Scholar
• Ramirez P, Garcia MA, Ferrer M, et al. Sequential measurements of procalcitonin levels in diagnosing ventilator-associated pneumonia. Eur Respir J. 2008;31:356–362. doi: 10.1183/09031936.00086707
   PubMed Web of Science ®Google Scholar
• Torres A, Niederman MS, Chastre J, et al. International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: Guidelines for the management of hospital-acquired pneumonia (Hap)/ventilator-associated pneumonia (VAP) of the European respiratory Society (ERS), European Society of Intensive Care Medicine (ESICM), European Society of clinical Microbiology and infectious Diseases (ESCMID) and Asociación Latinoamericana del Tórax (ALAT). Eur Respir J. 2017:50;1700582. doi: 10.1183/13993003.00582-2017
   PubMed Web of Science ®Google Scholar
• ADARPEF GFRUP, Leone M, Bouadma L, et al. Brief summary of French guidelines for the prevention, diagnosis and treatment of hospital-acquired pneumonia in ICU. Ann Intensive Care. 2018:8;104. doi: 10.1186/s13613-018-0444-0
   PubMed Web of Science ®Google Scholar
• Bouadma L, Luyt C-E, Tubach F, et al. Use of procalcitonin to reduce patients’ exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. 2010;375. 10.1016/S0140-6736(09)61879-1
   Google Scholar
• Layios N, Lambermont B, Canivet J-L, et al. Procalcitonin usefulness for the initiation of antibiotic treatment in intensive care unit patients*: Crit Care Med. 2012;40:2304–2309. doi: 10.1097/CCM.0b013e318251517a
   PubMed Web of Science ®Google Scholar
• Wirz Y, Meier MA, Bouadma L, et al. Effect of procalcitonin-guided antibiotic treatment on clinical outcomes in intensive care unit patients with infection and sepsis patients: a patient-level meta-analysis of randomized trials. Crit Care. 2018;22:191. doi: 10.1186/s13054-018-2125-7
   PubMed Web of Science ®Google Scholar
• Pinzone MR, Cacopardo B, Abbo L, et al. Optimal duration of antimicrobial therapy in ventilator-associated pneumonia: what is the role for procalcitonin? J Glob Antimicrob Resist. 2014;2:239–244. doi: 10.1016/j.jgar.2014.06.004
   PubMed Web of Science ®Google Scholar
• Liu D, Su L, Guan W, et al. Prognostic value of procalcitonin in pneumonia: a systematic review and meta‐analysis. Respirology. 2016;21:280–288. doi: 10.1111/resp.12704
   PubMed Web of Science ®Google Scholar
• Bloos F, Trips E, Nierhaus A, et al. Effect of sodium selenite administration and procalcitonin-guided therapy on mortality in patients with severe sepsis or septic shock: a randomized clinical trial. JAMA Intern Med. 2016;176(9):1266. doi: 10.1001/jamainternmed.2016.2514
   PubMed Web of Science ®Google Scholar
• Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the infectious diseases society of America and the American Thoracic Society. Clin Infect Dis. 2016;63:e61–111. doi: 10.1093/cid/ciw353
   PubMed Web of Science ®Google Scholar
• Executive summary: Surviving sepsis Campaign: International guidelines for the management of sepsis and septic shock 2021: Erratum. Crit Care Med. 2022;50:e413–4. doi: 10.1097/CCM.0000000000005513
   PubMed Web of Science ®Google Scholar
• Bouglé A, Tuffet S, Federici L, et al. Comparison of 8 versus 15 days of antibiotic therapy for Pseudomonas aeruginosa ventilator-associated pneumonia in adults: a randomized, controlled, open-label trial. Intensive care Med. 2022;48:841–849. doi: 10.1007/s00134-022-06690-5
   PubMed Web of Science ®Google Scholar
• Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: A randomized trial n.d.
   Google Scholar
• Nobre V, Harbarth S, Graf J-D, et al. Use of procalcitonin to shorten antibiotic treatment duration in septic patients: A randomized trial. Am J Respir Crit Care Med. 2008;177:498–505. doi: 10.1164/rccm.200708-1238OC
   PubMed Web of Science ®Google Scholar
• Stolz D, Smyrnios N, Eggimann P, et al. Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia: a randomised study. Eur Respir J. 2009;34:1364–1375. doi: 10.1183/09031936.00053209
   PubMed Web of Science ®Google Scholar
• Lam SW, Bauer SR, Fowler R, et al. Systematic review and meta-analysis of procalcitonin-guidance versus usual care for antimicrobial management in critically ill patients: focus on subgroups based on antibiotic initiation, cessation, or mixed strategies*. Crit Care Med. 2018;46:684–690. doi: 10.1097/CCM.0000000000002953
   PubMed Web of Science ®Google Scholar
• Schroeder S, Hochreiter M, Koehler T, et al. Procalcitonin (PCT)-guided algorithm reduces length of antibiotic treatment in surgical intensive care patients with severe sepsis: results of a prospective randomized study. Langenbecks Arch Surg. 2009;394:221–226. doi: 10.1007/s00423-008-0432-1
   PubMed Web of Science ®Google Scholar
• Hochreiter M, Köhler T, Schweiger A, et al. Procalcitonin to guide duration of antibiotic therapy in intensive care patients: a randomized prospective controlled trial. Crit Care. 2009;13:R83. doi: 10.1186/cc7903
   PubMed Web of Science ®Google Scholar
• Pepper DJ, Sun J, Rhee C, et al. Procalcitonin-guided antibiotic discontinuation and mortality in critically ill adults. Chest. 2019;155:1109–1118. doi: 10.1016/j.chest.2018.12.029
   PubMed Web of Science ®Google Scholar
• Assink-de Jong E, de Lange DW, van Oers JA, et al. Stop antibiotics on guidance of procalcitonin study (SAPS): a randomised prospective multicenter investigator-initiated trial to analyse whether daily measurements of procalcitonin versus a standard-of-care approach can safely shorten antibiotic duration in intensive care unit patients - calculated sample size: 1816 patients. BMC Infect Dis. 2013;13:178. doi: 10.1186/1471-2334-13-178
   PubMed Web of Science ®Google Scholar
• Kyriazopoulou E, Liaskou-Antoniou L, Adamis G, et al. Procalcitonin to reduce long-term infection-associated adverse events in sepsis. A randomized trial. Am J Respir Crit Care Med. 2021:203;202–210. doi: 10.1164/rccm.202004-1201OC
   PubMed Web of Science ®Google Scholar
• de Jong E, van Oers JA, Beishuizen A, et al. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial. Lancet Infect Dis. 2016:16;819–827. doi: 10.1016/S1473-3099(16)00053-0
   PubMed Web of Science ®Google Scholar
• Shehabi Y, Sterba M, Garrett PM, et al. Procalcitonin algorithm in critically ill adults with undifferentiated infection or suspected sepsis. A randomized controlled trial. Am J Respir Crit Care Med. 2014;190(10):1102–1110. doi: 10.1164/rccm.201408-1483OC
   PubMed Web of Science ®Google Scholar
• Kip MMA, van Oers JA, Shajiei A, et al. Cost-effectiveness of procalcitonin testing to guide antibiotic treatment duration in critically ill patients: results from a randomised controlled multicentre trial in the Netherlands. Crit Care. 2018;22(1):293. doi: 10.1186/s13054-018-2234-3
   PubMedGoogle Scholar
• Lee C-C, Kwa ALH, Apisarnthanarak A, et al. Procalcitonin (PCT)-guided antibiotic stewardship in Asia-Pacific countries: adaptation based on an expert consensus meeting. Clin Chem Lab Med CCLM. 2020:58;1983–1991. doi: 10.1515/cclm-2019-1122
   PubMed Web of Science ®Google Scholar
• Schuetz P, Beishuizen A, Broyles M, et al. Procalcitonin (PCT)-guided antibiotic stewardship: an international experts consensus on optimized clinical use. Clin Chem Lab Med CCLM. 2019;57(9):1308–1318. doi: 10.1515/cclm-2018-1181
   PubMed Web of Science ®Google Scholar
• Jensen JU, Hein L, Lundgren B, et al. Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit: a randomized trial*. Crit Care Med. 2011;39:2048–2058. doi: 10.1097/CCM.0b013e31821e8791
   PubMed Web of Science ®Google Scholar